LivaNova (NASDAQ:LIVN) Sets New 52-Week High – Time to Buy?

LivaNova PLC (NASDAQ:LIVN) reached a new 52-week high during trading on Thursday . The stock traded as high as $81.71 and last traded at $80.7470, with a volume of 38220 shares changing hands. The stock had previously closed at $79.95.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Needham & Company LLC upped their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. KeyCorp upped their price objective on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research note on Wednesday, February 25th. Finally, Barclays lifted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $80.75.

LivaNova Stock Up 3.1%

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a fifty day moving average price of $71.52 and a two-hundred day moving average price of $66.68. The company has a market cap of $4.53 billion, a P/E ratio of 42.37 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the prior year, the company posted $0.88 earnings per share. LivaNova’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, research analysts expect that LivaNova PLC will post 3.73 EPS for the current year.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. Hantz Financial Services Inc. lifted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming purchased a new stake in shares of LivaNova during the second quarter valued at approximately $31,000. EverSource Wealth Advisors LLC increased its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP bought a new stake in LivaNova during the third quarter worth $36,000. Finally, Covestor Ltd lifted its holdings in LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after acquiring an additional 392 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.